Learn more about the efficacy and role of adagrasib

Adagrasib (Adagrasib) is a powerful oral small molecule covalent inhibitor that binds to KRASG12C cysteine 12 residue, locking the protein in its inactive GDP-bound conformation, thereby blocking KRAS-dependent signaling and exerting anti-tumor efficacy in tumor models.

As the first kras 12c inhibitor approved by the FDA (U.S. Food and Drug Administration), sotoraxib has produced durable clinical benefit in kras 12c-mutant non-small cell lung cancer. In non-small cell lung cancer, the objective response rate of adagrasib（ORR） is better than that of sotorasib (sotorasib 37.1%, adagrasib 42.9%), their overall survival was （OS)（sotoraxib 12.5 months, adagrasib 12.6 months ) and median progression-free survival (PFS) (sotoraxib 6.8 months, adagrasib 6.5 months) were similar. In addition, pharmacological differences between adagrasib and sotoracib are drug half-life, dose-dependent prolonged exposure of adagrasib, and adagrasib's potential central nervous system (CNS) penetration. Approximately 27%‐42%‐42%‐Kras G12C mutant NSCLC patients have central nervous system metastases at diagnosis and have a poor prognosis.

Sinceadagrasibthe original drug has not yet been launched in China, patients can only purchase adagrasib through overseas channels, and the U.S. original version of 200mg*180 tablets is priced at hundreds of thousands of yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.